Core Viewpoint - The legal opinion letter from Zhejiang Tiance Law Firm confirms the legality and validity of the procedures and results of the annual general meeting of Tongce Medical Co., Ltd. for 2024 [1][2][6] Group 1: Meeting Procedures - The annual general meeting was proposed and convened by the board of directors, with the notice published on May 15, 2025 [2][3] - The meeting utilized a combination of on-site and online voting, with the on-site meeting scheduled for June 5, 2025, at 14:30 [2][3] - The online voting period was set for June 5, 2025, from 9:15 to 15:00 [3] Group 2: Attendance and Voting - Attendees included all registered shareholders from the Shanghai branch, with the option to appoint proxies who do not need to be shareholders [3][4] - A total of 3 individuals attended the meeting in person, representing 159,642,160 shares, approximately 35.6910% of the total share capital [4] - The total number of participants in the voting, including both on-site and online, was 595, representing 163,400,082 shares, approximately 36.5312% of the total share capital [4] Group 3: Voting Results - The voting process adhered to legal and regulatory requirements, with results announced on-site without objections from attendees [6] - The voting results for various proposals showed overwhelming support, with approval rates ranging from 99.7317% to 99.7649% [5][6] - The meeting did not vote on any matters not listed in the notice [6] Group 4: Conclusion - The legal opinion concludes that the meeting's convening, attendance qualifications, and voting procedures complied with relevant laws and regulations, confirming the validity of the voting results [6]

证券代码：600763 证券简称：通策医疗 公告编号：2025-011 通策医疗股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 595 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 163,400,082 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 36.5312 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长王毅女士主持本次股东大会。会议的召 开程序、表决方式等符合《公司法》及《公司章程》的有关规定。本次会议采取 现场结合网络的表决方式。 (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事7人，出席7人； 有限公司 2024 年年度报告摘要》 2、 ...

法律意见书 浙江天册律师事务所 关于 通策医疗股份有限公司 2024 年年度股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于 通策医疗股份有限公司 2024 年年度股东大会的 法律意见书 编号：TCYJS2025H0805 号 致：通策医疗股份有限公司 浙江天册律师事务所（以下简称"本所"）接受通策医疗股份有限公司（以 下简称"通策医疗"或"公司"）的委托，指派本所律师参加贵公司 2024 年年 度股东大会，并根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"）、中国证券监督管理委 员会《上市公司股东会规则》（以下简称"《股东会规则》"）等法律、法规和 其他有关规范性文件的要求出具本法律意见书。 在本法律意见书中，本所律师仅对本次股东大会表决程序及表决结果的合法 有效性发表意见，不对会议所审议的议案内容和该等议案中所表述的事实或数据 的真实性和准确性发表意见。 本法律意见书仅供 2024 年年度股东大会之 ...

Core Insights - Tongce Medical (600763) reported a closing price of 41.32 yuan as of May 30, 2025, reflecting a 0.29% increase from the previous week [1] - The company will hold its 2024 annual shareholders' meeting on June 5, 2025, to discuss various proposals [1][2] Financial Performance - In 2024, the company achieved operating revenue of 2.874 billion yuan, a year-on-year increase of 0.96% [2] - The net profit attributable to shareholders was 501 million yuan, representing a 0.20% year-on-year growth [2] - The company distributed a cash dividend of 4.50 yuan per 10 shares, totaling 201 million yuan, with a cash dividend ratio of 40.14% [2] Operational Highlights - The number of medical institutions under the company increased to 89, with 3,100 dental chairs and an outpatient volume of 3.5334 million visits, up 5.37% year-on-year [2] - The board of directors approved 35 proposals and held 10 meetings, while the supervisory board convened 8 times to oversee financial and operational management [2] Upcoming Events - The annual shareholders' meeting will address the 2024 annual report, profit distribution plan, financial settlement report, and the reappointment of the accounting firm [1][2]

Group 1 - The company will hold its annual shareholders' meeting on June 5, 2025, at 14:30, with both on-site and online voting options available [1][2] - The agenda includes the review and voting on several proposals, including the annual report, profit distribution plan, and financial statements [1][2][3] - The company aims to enhance its operational efficiency and digital transformation while focusing on cost reduction and resource integration [3][12] Group 2 - In 2024, the company achieved a revenue of 2.874 billion yuan, representing a year-on-year growth of 0.96%, and a net profit attributable to shareholders of 501.43 million yuan [3][21] - The company has expanded its dental chair installations to 3,100 and served 3.5334 million outpatient visits, marking a 5.37% increase [3][21] - The company plans to distribute a cash dividend of 4.50 yuan per 10 shares, pending shareholder approval [19][20] Group 3 - The company has outlined a strategic plan for 2025, focusing on customer value, resource optimization, and data-driven operations [12][15] - Key initiatives include the development of AI-driven healthcare solutions, enhancing patient management systems, and improving operational efficiency [13][18] - The company aims to establish a model for future hospitals, integrating advanced technologies and smart healthcare practices [15][17]

通策医疗股份有限公司 2024 年年度股东会资料 通策医疗股份有限公司 2024 年年度股东会 会议资料 通策医疗股份有限公司董事会 2025 年 6 月 5 日 1 通策医疗股份有限公司 2024 年年度股东会资料 通策医疗股份有限公司 2024 年年度股东会会议资料目录 一、程序文件 1. 大会会议议程 《通策医疗股份有限公司 2024 年度财务决算报告》； 二、提交股东会审议表决的议案 议案 1 《通策医疗股份有限公司 2024 年年度报告》和《通策医疗股份有限公司 2024 年年度报告摘要》； 议案 2 《通策医疗股份有限公司 2024 年度董事会工作报告》； 议案 3 《通策医疗股份有限公司 2024 年度利润分配方案》； 议案 4 议案 5 《通策医疗股份有限公司关于续聘会计师事务所的议案》； 议案 6 《通策医疗股份有限公司 2024 年度监事会工作报告》； 议案 7 《通策医疗股份有限公司关于修订<公司章程>的议案》。 35 通策医疗股份有限公司 2024 年年度股东会资料 通策医疗股份有限公司 2024 年年度股东会议程 一、现场会议时间： 2025 年 6 月 5 日（星期四）下午 14 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Tongce Medical, which operates in the dental healthcare sector [1][2] - As of May 16, Tongce Medical's closing price was 40.62 yuan, with a decline of 1.43%, resulting in a rolling PE ratio of 35.47 times and a total market capitalization of 18.169 billion yuan [1] - The average PE ratio for the healthcare services industry is 37.33 times, with a median of 39.22 times, positioning Tongce Medical at 26th place within the industry [1][2] Group 2 - As of the first quarter of 2025, 21 institutions held shares in Tongce Medical, including 18 funds, with a total holding of 209.5898 million shares valued at 9.488 billion yuan [1] - The main business of Tongce Medical includes providing dental healthcare services and research, with key products being medical services, product sales, construction engineering, and comprehensive service fees [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 745 million yuan, a year-on-year increase of 5.11%, and a net profit of 184 million yuan, reflecting a year-on-year growth of 6.22%, with a gross profit margin of 44.21% [1]

Summary of Key Points Core Viewpoint - The announcement details the stock pledge and release of shares by the controlling shareholder, Baohun Industrial Group, which holds a significant portion of the shares in Tongce Medical Co., Ltd. The company assures that the pledge will not affect its main business or operational capabilities. Group 1: Shareholding and Pledge Details - Baohun Industrial holds a total of 151,589,199 shares, accounting for 33.89% of the total share capital of Tongce Medical [1] - The number of shares pledged this time is 6,860,000, which represents 4.53% of Baohun Industrial's holdings and 1.53% of the total shares of the company [1] - The total number of shares previously pledged by Baohun Industrial is 97,725,507, which is 64.47% of its holdings and 21.85% of the total shares of the company [1][2] Group 2: Pledge and Release Transactions - After the current pledge and release transactions, the cumulative pledged shares by Baohun Industrial and its concerted actors will be as follows: 15,368,028.7 shares, which is 34.36% of the total share capital [2] - The remaining pledged shares after the release will be 9,772,550.7 shares, which is 63.59% of Baohun Industrial's holdings and 21.85% of the total shares of the company [2] Group 3: Financial Stability and Risk Management - Baohun Industrial has a good credit status and repayment capability, indicating that the pledge risk is controllable and will not impact the company's main business or operational continuity [3] - The company will take measures such as supplementary pledges or early repurchase of pledged shares to manage any potential risks [3]

通策医疗股份有限公司 证券简称：通策医疗 证券代码：600763 编号：临 2025-010 关于控股股东部分股票质押及解除质押的公告 1 股东 名称 是否为 控股股 东 本次质 押股数 （万股） 是否 为限 售股 是否 补充 质押 质押起始日 质押到期日 质权人 占其所 持股份 比例 占公司 总股本 比例 质押融资资 金用途 宝群 实业 是 686 否 否 2025.5.13 2026.5.11 中国光大银行 股份有限公司 杭州分行 4.53% 1.53% 体系外医 疗项目资 金需要 1.股份质押基本情况 2.解除质押基本情况 | 股东名称 | 宝群实业 | | --- | --- | | 本次解质股份 | 616.2618 万股 | | 占其所持股份比例 | 4.07% | | 占公司总股本比例 | 1.38% | | 解质时间 | 2025.5.16 | | 持股数量 | 15158.9199 万股 | | 持股比例 | 33.89% | | 剩余被质押股份数量 | 9772.5507 万股 | | 剩余被质押股份数量占其所持股份比例 | 64.47% | | 剩余被质押股份数量占公司总股本比例 | 2 ...

Core Viewpoint - The announcement from Tongce Medical indicates significant share pledges and releases by its major shareholder, Hangzhou Baoqun Industrial Group, which holds 33.89% of the company's total shares [1] Group 1: Shareholding and Pledge Details - Hangzhou Baoqun Industrial Group holds a total of 152 million shares in Tongce Medical, representing 33.89% of the total share capital [1] - The number of pledged shares is 6.86 million, accounting for 4.53% of Baoqun's holdings and 1.53% of the total shares of the company [1] - The number of released pledged shares is 6.1626 million, which is 4.07% of Baoqun's holdings and 1.38% of the total shares [1] Group 2: Pledge Statistics - The total number of pledged shares by Baoqun is 97.7255 million, which is 64.47% of its holdings and 21.85% of the total shares of Tongce Medical [1] - The future six-month maturity of pledged shares amounts to 63.940276 million, representing 42.18% of Baoqun's holdings and 14.30% of the total shares [1] - The total number of pledged shares maturing within one year is 97.725507 million, which is 64.47% of Baoqun's holdings and 21.85% of the total shares [1] Group 3: Financial Health and Control - There are no indications of non-operational fund occupation, illegal guarantees, or related party transactions that could harm the interests of the listed company [1] - Baoqun Industrial Group has a good credit status and repayment capability, indicating that the pledge risk is controllable [1] - The pledges will not impact the main business operations or the ongoing viability of Tongce Medical, nor will they lead to a change in actual control of the company [1]